Document Detail

Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries.
MedLine Citation:
PMID:  18095745     Owner:  NLM     Status:  MEDLINE    
Pregnancy registries are the most commonly used data resource for the post-marketing surveillance of drug teratogenicity. However, the limited sample size and potential selection bias in these registries has led us to investigate the potential of the UK General Practice Research Database (GPRD) as an alternative data source for monitoring drug safety during pregnancy. In addition, a literature review identified further observational data sources that monitor pregnancy outcomes for future evaluation. Initial feasibility studies focused on the ability of the GPRD to capture pregnancy outcomes for a range of drug class exposures, all of which are currently under investigation in pregnancy registries, during pregnancy. The comparator pregnancy registries were identified via a MEDLINE search, whilst eligible pregnancies, in which women received one or more prescriptions for the drug of interest during pregnancy, were identified in the GPRD using the mother-baby link. The number of pregnancy outcomes following exposure to medication for a range of conditions with varying prevalence, including depression, migraine, epilepsy, herpes simplex and HIV, captured by the two data sources were compared. For depression, a relatively prevalent condition, the GPRD recorded the same number of mean annual intrauterine exposures to fluoxetine as the pregnancy registry (118 exposures/year). Ascertainment of intrauterine exposure to drug treatments for less prevalent conditions was found to be higher for the pregnancy registries than the GPRD; for the older antiepileptic drugs (valproate and carbamazepine), the pregnancy registry recorded between four and five times as many mean annual exposures as the GPRD. Virtually no antiretroviral exposures (three) were identified during the time period of interest on the GPRD, compared with 3946 in the Antiretroviral Pregnancy Registry. Data from the GPRD meet established criteria for evaluating outcomes of pregnancy. For prevalent conditions, it has the potential to replace or work alongside standard pregnancy registries and the alternative data sources identified. Further studies are now needed to assess its ability to replicate known teratogenic associations.
Rachel A Charlton; Marianne C Cunnington; Corinne S de Vries; John G Weil
Related Documents :
21041865 - Drugs in pregnancy--the issues for 2010.
16104005 - Combined chemotherapy and teratogenicity.
16614625 - The safety of psychotropic drug use during pregnancy: a review.
11365385 - Notice on efavirenz and pregnancy.
22447695 - Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biom...
18303215 - Transient acquired hemophilia associated with mycoplasma pneumoniae pneumonia.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  31     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2008  
Date Detail:
Created Date:  2007-12-21     Completed Date:  2008-05-05     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  39-51     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Databases, Factual / statistics & numerical data*
Drug-Related Side Effects and Adverse Reactions*
Great Britain / epidemiology
Pregnancy Outcome
Prenatal Exposure Delayed Effects / chemically induced*,  epidemiology
Product Surveillance, Postmarketing / methods,  statistics & numerical data
Registries / statistics & numerical data*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Methods for causality assessment of adverse drug reactions: a systematic review.
Next Document:  Orlistat-associated adverse effects and drug interactions: a critical review.